| From The Cochrane Library, Issue 3, 2003. Oxford: Update Software Ltd. All rights reserved. | |||||||
A comparison of active drugs for the treatment of dysthymia (Cochrane Review)Lima MS, Hotopf M |
| ||||||
A substantive amendment to this systematic review was last made on 27 April 2003. Cochrane reviews are regularly checked and updated if necessary.Background: Many drug treatments have been proposed for the treatment of dysthymia, but with so many potential comparisons it is not possible at the present time to determine which is the treatment of choice. There is a need to know whether the different classes of antidepressants have similar efficacy. In addition, the tolerability of treatments may be even more important, since dysthymia is a chronic condition characterised by less severe symptoms than major depression.
Objectives: To conduct a systematic review of all randomised controlled trials comparing two or more active drug treatments for dysthymia.
Search strategy: Electronic searches of Cochrane Library, EMBASE, MEDLINE, PsycLIT and LILACS, Biological Abstracts; reference searching; personal communication; unpublished trials from pharmaceutical industry.
Selection criteria: Only randomised and quasi-randomised controlled trials were included. Trials had to compare at least two active drug treatments in the treatment of dysthymia. Exclusion criteria were: non-randomised studies, studies which included patients with mixed major depression/dysthymia and studies on depression/dysthymia secondary to other disorders (e.g. substance abuse).
Data collection and analysis: The reviewers extracted the data independently and odds ratios, weighted mean difference and number needed to treat were estimated. The reviewers assumed that people who died or dropped out had no improvement and tested the sensitivity of the final results to this assumption.
Main results: A total of 14 trials were eligible for inclusion in the review. All studied drugs promoted similar clinical responses, although with different side effect profiles. The evidence for TCAs and SSRIs was the most robust, considering the number of trials and participants.
Reviewers' conclusions: The conclusion is that the choice of drug must be made based on consideration of drug-specific side effect properties.
Citation: Lima MS, Hotopf M. A comparison of active drugs for the treatment of dysthymia (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
This is an abstract of a regularly updated, systematic review prepared and maintained by the Cochrane Collaboration. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).The Cochrane Library is designed and produced by Update Software Ltd. Update Software Ltd, Summertown Pavilion, Middle Way, Oxford OX2 7LG, UK
(Tel:+44 1865 513902; Fax:+44 1865 516918)File Reference: AB004047.htm